Caixia Yang,1 Chenlin Ma,1 Yingchun Li,1 Peng Mo,1 Yusheng Yangtwo
1Division of Stomatology, Qinghai province people’s Hospital, Qinghai, People’s Republic of China twoDivision of Pathology, Ninbo Yinzhou No. two Hospital, Ninbo, People’s Republic of China
Background: Numerous research have explored the prognostic worth of T-cell lymphoma invasion and metastasis inducing aspect 1 (Tiam1) and its association with lymphatic metastasis in malignant strong tumors, but the conclusions stay controversial. Thus, we performed a meta-evaluation to systematically assess the prognostic worth of Tiam1 expression and its association with lymphatic metastasis in malignant strong tumors.
Procedures: We searched eligible research in PubMed, Internet of Science and EMBASE databases (from inception up to October 2018). The combined HR with 95% CI was utilised to estimate the prognostic worth of Tiam1 expression. The correlation involving Tiam1 expression and lymphatic metastasis was assessed applying the combined odds ratio (OR) with 95% CI.
Benefits: A total of 17 research with two,228 individuals with strong tumors had been integrated in this meta-evaluation. The general estimated benefits showed that higher Tiam1 expression was considerably linked with shorter general survival (HR= 2.08, 95% CI: 1.62–2.68, P<0.01), and illness-no cost survival (HR = 1.86, 95% CI: 1.49–2.32, P<0.01). Apart from, we also identified that there was a close partnership involving higher Tiam1 expression and good lymphatic metastasis (OR=two.63 95% CI: 1.79–3.84, P<0.01).
Conclusion: Higher Tiam1 expression was considerably linked with shorter survival and good lymphatic metastasis in individuals with malignant strong tumors. Thus, Tiam1 could be a promising prognostic biomarker and an helpful therapeutic target for malignant strong tumors.
Keyword phrases: tumor, Tiam1, survival, meta-evaluation
This function is published and licensed by Dove Health-related Press Restricted. The complete terms of this license are readily available at https://www.dovepress.com/terms.php and incorporate the Inventive Commons Attribution – Non Industrial (unported, v3.) License.
By accessing the function you hereby accept the Terms. Non-industrial makes use of of the function are permitted with no any additional permission from Dove Health-related Press Restricted, supplied the function is effectively attributed. For permission for industrial use of this function, please see paragraphs four.two and five of our Terms.